This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
High levels of antibodies to the 65-kd isoform of glutamic acid decarboxylase (GAD65) are observed in some cases of sporadic, progressive cerebellar ataxia and suggest a potential autoimmune etiology.1-3 Few studies have examined immunotherapy in GAD65-associated ataxia.1,4 We describe a patient with GAD65 ataxia who responded to IV methylprednisolone (IVMP) but not to plasma exchange. Oral azathioprine has provided a sustained clinical remission.
Case report.
A 70-year-old man with type 2 diabetes mellitus and unremarkable family history presented with 9 months of progressive ataxia, beginning with left hemiataxia and dysarthria. He later developed right hemiataxia, progressive gait instability, dysmetria, spasticity, worsening dysarthria, and dysphagia with 5- to 10-kg weight loss.
On exam he had loud, scanning, dysarthric speech, gaze-evoked nystagmus, saccadic intrusions, dysmetric saccades, spastic tone and bilateral Babinski signs, marked left greater than right limb ataxia with gross action tremor, dysmetria, and dysdiadokinesia (video). He was unable to stand or walk because of ataxia and received a gastrostomy tube for dysphagia and aspiration. His score on the International Cooperative Ataxia Rating Scale (ICARS) was 78 of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
